Mannatech (MTEX) Competitors $9.41 -0.15 (-1.61%) Closing price 06/13/2025 03:50 PM EasternExtended Trading$9.30 -0.10 (-1.07%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTEX vs. CRVO, ANRO, VTGN, SRZN, SKYE, MNOV, ZURA, BYSI, IMRX, and IMUXShould you be buying Mannatech stock or one of its competitors? The main competitors of Mannatech include CervoMed (CRVO), Alto Neuroscience (ANRO), Vistagen Therapeutics (VTGN), Surrozen (SRZN), Skye Bioscience (SKYE), MediciNova (MNOV), Zura Bio (ZURA), BeyondSpring (BYSI), Immuneering (IMRX), and Immunic (IMUX). These companies are all part of the "pharmaceutical products" industry. Mannatech vs. Its Competitors CervoMed Alto Neuroscience Vistagen Therapeutics Surrozen Skye Bioscience MediciNova Zura Bio BeyondSpring Immuneering Immunic CervoMed (NASDAQ:CRVO) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings, institutional ownership and community ranking. Does the MarketBeat Community believe in CRVO or MTEX? Mannatech received 304 more outperform votes than CervoMed when rated by MarketBeat users. Likewise, 77.65% of users gave Mannatech an outperform vote while only 76.47% of users gave CervoMed an outperform vote. CompanyUnderperformOutperformCervoMedOutperform Votes2676.47% Underperform Votes823.53% MannatechOutperform Votes33077.65% Underperform Votes9522.35% Do analysts recommend CRVO or MTEX? CervoMed currently has a consensus price target of $27.63, indicating a potential upside of 287.99%. Given CervoMed's stronger consensus rating and higher possible upside, research analysts plainly believe CervoMed is more favorable than Mannatech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CervoMed 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89Mannatech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, CRVO or MTEX? CervoMed has a beta of -0.73, suggesting that its share price is 173% less volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Do institutionals and insiders hold more shares of CRVO or MTEX? 25.1% of CervoMed shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 35.4% of CervoMed shares are owned by company insiders. Comparatively, 41.5% of Mannatech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher valuation and earnings, CRVO or MTEX? CervoMed has higher earnings, but lower revenue than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than CervoMed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCervoMed$7.14M8.68-$2.17M-$2.18-3.27Mannatech$115.04M0.16-$2.24M-$0.10-94.06 Is CRVO or MTEX more profitable? Mannatech has a net margin of -1.26% compared to CervoMed's net margin of -118.68%. Mannatech's return on equity of -15.62% beat CervoMed's return on equity.Company Net Margins Return on Equity Return on Assets CervoMed-118.68% -44.11% -39.81% Mannatech -1.26%-15.62%-3.76% Does the media refer more to CRVO or MTEX? In the previous week, CervoMed had 6 more articles in the media than Mannatech. MarketBeat recorded 8 mentions for CervoMed and 2 mentions for Mannatech. Mannatech's average media sentiment score of 1.44 beat CervoMed's score of 0.77 indicating that Mannatech is being referred to more favorably in the news media. Company Overall Sentiment CervoMed Positive Mannatech Positive SummaryMannatech beats CervoMed on 10 of the 19 factors compared between the two stocks. Get Mannatech News Delivered to You Automatically Sign up to receive the latest news and ratings for MTEX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTEX vs. The Competition Export to ExcelMetricMannatechMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.88M$1.23B$5.57B$8.50BDividend YieldN/AN/A5.28%4.16%P/E Ratio-11.6112.8226.6319.64Price / Sales0.1611.01407.99152.17Price / CashN/A10.4038.2534.64Price / Book1.671.446.964.60Net Income-$2.24M-$56.07M$3.23B$248.06M7 Day Performance-6.78%-3.94%-1.13%-0.94%1 Month Performance-15.75%-1.45%8.59%3.52%1 Year Performance17.87%-33.84%33.63%14.02% Mannatech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTEXMannatech1.4785 of 5 stars$9.41-1.6%N/A+17.9%$17.88M$115.04M-11.61250Short Interest ↓Gap DownCRVOCervoMed3.202 of 5 stars$8.16+13.0%$27.63+238.5%-64.0%$71.02M$7.14M-3.744News CoverageAnalyst ForecastShort Interest ↓ANROAlto Neuroscience1.6676 of 5 stars$2.60+0.8%$15.40+492.3%-79.9%$70.39MN/A-1.11N/AVTGNVistagen Therapeutics1.0493 of 5 stars$2.42-6.2%N/A-37.2%$69.85M$698K-1.6440News CoveragePositive NewsGap DownSRZNSurrozen3.8053 of 5 stars$8.13-4.2%$38.50+373.6%-15.9%$69.62M$11.64M-0.3380Positive NewsSKYESkye Bioscience1.7913 of 5 stars$2.24+13.1%$16.60+641.1%-80.9%$69.38MN/A-2.7311Analyst RevisionMNOVMediciNova2.1096 of 5 stars$1.41+1.4%$9.00+538.3%-2.9%$69.16M$1M-6.1310Positive NewsZURAZura Bio2.6395 of 5 stars$1.01flat$14.33+1,319.1%-67.8%$69.06MN/A-1.443Analyst RevisionGap UpBYSIBeyondSpringN/A$1.70-2.3%N/A+11.6%$68.70M$1.88M0.0080Positive NewsGap DownIMRXImmuneering3.0303 of 5 stars$1.87+9.4%$15.33+720.0%+12.4%$67.29M$320K-0.9560News CoveragePositive NewsShort Interest ↑IMUXImmunic3.1776 of 5 stars$0.70+6.1%$11.60+1,557.1%-34.6%$67.07MN/A-0.5770Short Interest ↑ Related Companies and Tools Related Companies CRVO Alternatives ANRO Alternatives VTGN Alternatives SRZN Alternatives SKYE Alternatives MNOV Alternatives ZURA Alternatives BYSI Alternatives IMRX Alternatives IMUX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTEX) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mannatech, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Mannatech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
